Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002593 · ClinicalTrials.gov registry record · Phase 3

S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed

A Phase 3 study, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 3
Development phase
1,135
Enrollment target

NCT00002593 is a Phase 3 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 1,135 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002593, a Phase 3 study, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 3
Development phase
1,135 participants
Enrollment target

Study Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy given in different ways in treating patients with surgically removed stage II or stage III colon cancer at high risk of recurrence.

Interventions

  • DRUG fluorouracil
  • DRUG leucovorin calcium
  • DRUG levamisole hydrochloride

Trial Details

FieldValue
Enrollment Target 1,135 participants
Start Date 1994-12
Est. Completion 2005-03
Phase Phase 3

Sponsor

SWOG Cancer Research Network

270 total trials

What the Registry Record Tells You About NCT00002593

The ClinicalTrials.gov registry entry for NCT00002593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,135 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which fluorouracil is the first listed.

NCT00002593 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00002593 about?

NCT00002593 is a clinical study titled "S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving drugs in different ways may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy given ...

What is the current status of trial NCT00002593?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,135 participants. The study started on 1994-12. Estimated completion is 2005-03.

What interventions are being tested in trial NCT00002593?

The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), levamisole hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00002593?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.